Brokerages Set Moderna, Inc. (NASDAQ:MRNA) Price Target at $126.49

Shares of Moderna, Inc. (NASDAQ:MRNA) have been given an average recommendation of “Hold” by the sixteen ratings firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $129.55.

MRNA has been the subject of several recent research reports. Canaccord Genuity Group raised their price target on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research report on Friday. Oppenheimer lifted their target price on Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a report on Friday. William Blair restated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. HSBC reiterated a “reduce” rating and issued a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Finally, Royal Bank of Canada upped their target price on shares of Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a research note on Friday.

Insider Buying and Selling

In other news, CFO James M. Mock sold 647 shares of Moderna stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares in the company, valued at $406,651. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the sale, the president now owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO James M. Mock sold 647 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares of the company’s stock, valued at approximately $406,651. The disclosure for this sale can be found here. Insiders have sold 139,954 shares of company stock worth $14,822,576 in the last ninety days. 15.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Moderna

Hedge funds have recently made changes to their positions in the business. Allworth Financial LP raised its stake in Moderna by 6.5% during the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after acquiring an additional 101 shares during the last quarter. TIAA Trust National Association increased its holdings in shares of Moderna by 2.3% in the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after purchasing an additional 102 shares during the period. Principle Wealth Partners LLC raised its stake in shares of Moderna by 4.3% during the first quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock worth $266,000 after purchasing an additional 102 shares during the last quarter. Sound Income Strategies LLC raised its stake in shares of Moderna by 17.8% during the fourth quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock worth $76,000 after purchasing an additional 115 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Moderna by 32.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock worth $47,000 after purchasing an additional 116 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

NASDAQ:MRNA opened at $125.00 on Thursday. The company has a market capitalization of $47.86 billion, a P/E ratio of -7.98 and a beta of 1.57. The company has a quick ratio of 3.36, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. Moderna has a 52 week low of $62.55 and a 52 week high of $142.79. The stock’s fifty day moving average is $105.05 and its two-hundred day moving average is $94.42.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.59) by $0.52. The firm had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. Moderna’s revenue was down 91.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.19 EPS. Equities analysts expect that Moderna will post -7.51 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.